[1] 李然, 王德良, 王文素.术前强化阿托伐他汀联合充分水化疗法对PCI术后并发造影剂肾病的影响[J].河北医科大学学报, 2017, 38(3):262. doi: 10.3969/j.issn.1007-3205.2017.03.004
[2] DEMIRTAS L, TURKMEN K, KANDEMIR FM, et al.The possible role of interleukin-33 as a new player in the pathogenesis of contrast-induced nephropathy in diabetic rats[J].Ren Fail, 2016, 38(6):952. doi: 10.3109/0886022X.2016.1165034
[3] 周嫦英, 徐志锋, 潘爱珍.三种不同水化治疗对预防2型糖尿病病人造影剂肾病的影响[J].护理实践与研究, 2018, 15(4):34. doi: 10.3969/j.issn.1672-9676.2018.04.013
[4] WRÓBEL W, SINKIEWICZ W, GORDON M, et al.Oral versus intravenous hydration and renal function in diabetic patients undergoing percutaneous coronary interventions[J].Kardiol Pol, 2010, 68(9):1015.
[5] STACUL F, VAN DER MOLEN AJ, REIMER P, et al.Contrast induced nephropathy:updated ESUR contrast media safety committee guidelines[J].Eur Radiol, 2011, 21(12):2527. doi: 10.1007/s00330-011-2225-0
[6] 张鹏, 张瑞妮, 李飞, 等.血清胱抑素C在冠状动脉介入术后早期造影剂肾病中的诊断价值[J].检验医学与临床, 2018, 15(16):2475. doi: 10.3969/j.issn.1672-9455.2018.16.035
[7] RIBICHINI F, GAMBARO G, GRAZIANI MS, et al.Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced nephropathy after coronary angiography and interventions[J].Clin Chem, 2012, 58(2):458. doi: 10.1373/clinchem.2011.170464
[8] KARAMAN A, DIYARBAKIR B, DURUR-SUBASI I, et al.A novel approach to contrast-induced nephrotoxicity:the melatonergic agent agomelatine[J].Br J Radiol, 2016, 89(1061):20150716. doi: 10.1259/bjr.20150716
[9] 祖玉刚, 赵淑君, 张芳, 等.匹伐他汀联合乙酰半胱氨酸对PCI病人对比剂肾功能损伤的干预作用[J].山东医药, 2018, 58(33):55. doi: 10.3969/j.issn.1002-266X.2018.33.016
[10] BENZER M, ALPAY H, BAYKANÖ, et al.Serum NGAL, cystatin C and urinary NAG measurements for early diagnosis of contrast-induced nephropathy in children[J].Ren Fail, 2016, 38(1):27. doi: 10.3109/0886022X.2015.1106846
[11] 马益敏, 肖玲, 傅荣春, 等.优化护理在TACE术水化治疗预防对比剂肾病中的效果观察[J].实用临床医药杂志, 2017(20):165.
[12] 冯亚新, 侯岩芳, 王玲玲, 等.PCI术前, 术后口服水化补液预防CIN效果观察与护理[J].齐鲁护理杂志(上旬刊), 2011, 17(12):21.